Business, Liquidity and Capital Resources	12 Months Ended
Dec. 31, 2020
Business, Liquidity and Capital Resources [Abstract]
BUSINESS, LIQUIDITY AND CAPITAL RESOURCES	NOTE 1 – BUSINESS, LIQUIDITY AND CAPITAL RESOURCES Overview Protara Therapeutics, Inc. and its consolidated subsidiaries ("Protara" or the "Company") is committed to identifying and advancing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara's portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). The third program in the portfolio is Intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure associated liver disease (IFALD). The fourth program in the portfolio is Vonapanitase, a recombinant human elastase. On January 9, 2020, privately-held ArTara Subsidiary, Inc. ("Private ArTara") and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed the merger and reorganization (the "Merger"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated September 23, 2019, (the "Merger Agreement") by and among Protara Therapeutics, Inc., Private ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc ("Merger Sub"). Thereupon, Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara Therapeutics, Inc. On January 9, 2020, in connection with and prior to the completion of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the "Protara Reverse Stock Split"), Private ArTara changed its name from "ArTara Therapeutics, Inc." to "ArTara Subsidiary, Inc.", and ArTara Therapeutics, Inc. changed its name from "Proteon Therapeutics, Inc." to "ArTara Therapeutics, Inc" then subsequently changed its name from "ArTara Therapeutics, Inc" to "Protara Therapeutics, Inc." All share and per share amounts presented in this annual report on Form 10-K have been adjusted to reflect the Protara Reverse Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined below), all of the outstanding shares of Protara Therapeutics, Inc.'s Series A Preferred Stock were converted into shares of Protara Therapeutics, Inc.'s Common Stock (defined below). Shares of the Company's Common Stock commenced trading on The Nasdaq Capital Market under the new name and ticker symbol "TARA" as of market open on January 10, 2020. See Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization. Liquidity, Capital Resources and Management Plans As of December 31, 2020 and 2019, the Company's cash and cash equivalents was $168,598 and $564, respectively. The Company has not generated revenues since its inception and has incurred net losses of $33,978 and $7,830 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company had working capital of $166,520 and stockholder's equity of $199,243. During the year ended December 31, 2020, cash flows used in operating activities were $23,407, consisting primarily of a net loss of $33,978, which includes non-cash stock-based compensation charges of $9,746. Since inception, the Company has met its liquidity requirements principally through the sale of its Common Stock and Series 1 Convertible Preferred Stock. In connection with the Merger, the Company consummated the Private Placements, raising gross proceeds of $42.5 million and proceeds, net of offering costs, of $39.6 million. On September 22, 2020, the Company entered into underwriting agreements with Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of several underwriters for separate, concurrent underwritten public offerings of the Company's Common Stock and Series 1 Convertible Preferred Stock. On September 24, 2020, gross and net proceeds from this offering were $147.6 million and $139.9 million, respectively. On October 6, 2020, the underwriters exercised their overallotment option, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1 million, respectively (See Note 8). The Company is in the business of developing biopharmaceuticals and has no current or near term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management's plans. The Company believes that its current financial resources are sufficient to satisfy the Company's estimated liquidity needs for at least twelve months from the date of issuance of these consolidated financial statements.

Business, Liquidity and Capital Resources

12 Months Ended

Dec. 31, 2020

Business, Liquidity and Capital Resources [Abstract]

BUSINESS, LIQUIDITY AND CAPITAL RESOURCES

NOTE 1 – BUSINESS, LIQUIDITY AND CAPITAL RESOURCES

Overview

Protara Therapeutics, Inc. and its consolidated subsidiaries ("Protara" or the "Company") is committed to identifying and advancing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara's portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). The third program in the portfolio is Intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure associated liver disease (IFALD). The fourth program in the portfolio is Vonapanitase, a recombinant human elastase.

On January 9, 2020, privately-held ArTara Subsidiary, Inc. ("Private ArTara") and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed the merger and reorganization (the "Merger"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated September 23, 2019, (the "Merger Agreement") by and among Protara Therapeutics, Inc., Private ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc ("Merger Sub"). Thereupon, Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara Therapeutics, Inc.

On January 9, 2020, in connection with and prior to the completion of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the "Protara Reverse Stock Split"), Private ArTara changed its name from "ArTara Therapeutics, Inc." to "ArTara Subsidiary, Inc.", and ArTara Therapeutics, Inc. changed its name from "Proteon Therapeutics, Inc." to "ArTara Therapeutics, Inc" then subsequently changed its name from "ArTara Therapeutics, Inc" to "Protara Therapeutics, Inc." All share and per share amounts presented in this annual report on Form 10-K have been adjusted to reflect the Protara Reverse Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined below), all of the outstanding shares of Protara Therapeutics, Inc.'s Series A Preferred Stock were converted into shares of Protara Therapeutics, Inc.'s Common Stock (defined below). Shares of the Company's Common Stock commenced trading on The Nasdaq Capital Market under the new name and ticker symbol "TARA" as of market open on January 10, 2020. See Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization.

Liquidity, Capital Resources and Management Plans

As of December 31, 2020 and 2019, the Company's cash and cash equivalents was $168,598 and $564, respectively. The Company has not generated revenues since its inception and has incurred net losses of $33,978 and $7,830 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company had working capital of $166,520 and stockholder's equity of $199,243. During the year ended December 31, 2020, cash flows used in operating activities were $23,407, consisting primarily of a net loss of $33,978, which includes non-cash stock-based compensation charges of $9,746. Since inception, the Company has met its liquidity requirements principally through the sale of its Common Stock and Series 1 Convertible Preferred Stock.

In connection with the Merger, the Company consummated the Private Placements, raising gross proceeds of $42.5 million and proceeds, net of offering costs, of $39.6 million.

On September 22, 2020, the Company entered into underwriting agreements with Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of several underwriters for separate, concurrent underwritten public offerings of the Company's Common Stock and Series 1 Convertible Preferred Stock. On September 24, 2020, gross and net proceeds from this offering were $147.6 million and $139.9 million, respectively. On October 6, 2020, the underwriters exercised their overallotment option, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1 million, respectively (See Note 8).

The Company is in the business of developing biopharmaceuticals and has no current or near term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management's plans.

The Company believes that its current financial resources are sufficient to satisfy the Company's estimated liquidity needs for at least twelve months from the date of issuance of these consolidated financial statements.